Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Qutenza (8% capsaicin) Clear all
Completed Phase 2 Interventional Results available

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

NCT01260454
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Qutenza (8% capsaicin)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
15 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 4, 2026, 11:38 PM EDT
Not yet recruiting Phase 4 Interventional

High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy

NCT07834281
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
High Concentration Capsaicin Patch (HCCP), Placebo patch
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 11:38 PM EDT
Enrolling by invitation No phase listed Observational

Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

NCT06540456
View directory record Official record
Conditions
Lower Back Pain, Lumbosacral Radiculopathy
Interventions
Qutenza® 8% Capsaicin Topical System
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

NCT04967664
View directory record Official record
Conditions
Post Surgical Neuropathic Pain
Interventions
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • Vista, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers

NCT01981395
View directory record Official record
Conditions
Hyperalgesia, Allodynia
Interventions
Fenobam, Placebo
Drug
Lead sponsor
Laura Cavallone
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 4, 2026, 11:38 PM EDT
Recruiting Not applicable Interventional

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

NCT04142177
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
Other · Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 4, 2026, 11:38 PM EDT
Active, not recruiting No phase listed Observational

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

NCT06495424
View directory record Official record
Conditions
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions
Capsaicin 8%
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain

NCT02441660
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Capsaicin 8% Patch, Low Dose Capsaicin 0.025% Well Patch
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Sickle Cell Pain: Intervention With Capsaicin Exposure

NCT03899246
View directory record Official record
Conditions
Neuropathic Pain, Sickle Cell Disease
Interventions
Eight Percent Topical Capsaicin
Drug
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
14 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

NCT00916942
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thermosensitivity of a Topical Palmitated Formulation of Capsaicin

NCT05649228
View directory record Official record
Conditions
Pain Management
Interventions
Capsaicin 0.1% Cream, Capsaicin Palmitate 0.25% Cream, Placebo Cream
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Normal Breathing and Swallowing in Healthy Volunteers

NCT03122145
View directory record Official record
Conditions
Healthy
Interventions
Capsaicin, Videofluoroscopic swallow study
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 4, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

NCT03576508
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 4, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 4, 2026, 11:38 PM EDT